Finance & valuation

Latest content

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver

16 December 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models

12 December 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment

03 December 2020

Auction of Gionee’s smartphone patents a reality check for China

IP assets of bankrupt firm, once a big local handset seller, changed hands at fire-sale prices

25 November 2020

In  Blackberry patent sale, Canada sees loss of prestige not value creation opportunity

Possible deal comes during a period of concern in the country over loss of tech crown jewels, engineering talent and the bleeding of IP assets

20 November 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations

19 November 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making

17 November 2020

Under sanctions pressure, Huawei sells off entry level smartphone brand to government

Company has sold its Honor handset unit to a consortium backed by local authorities in Shenzhen government, a move that will take a big chunk out of its sales figures

17 November 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation

10 November 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome

09 November 2020

Get unlimited access to all IAM content